TY - JOUR
T1 - Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia
T2 - Preliminary results
AU - Khouri, Issa F.
AU - Keating, Michael J.
AU - Vriesendorp, Huibert M.
AU - Reading, Christopher L.
AU - Przepiorka, Donna
AU - Huh, Yang O.
AU - Andersson, Borje S.
AU - Van Besien, Koen W.
AU - Mehra, Rakesh C.
AU - Giralt, Sergio A.
AU - Ippoliti, Cindy
AU - Marshall, Marty
AU - Thomas, Michael W.
AU - O'Brien, Susan
AU - Robertson, Lester E.
AU - Deisseroth, Albert B.
AU - Champlin, Richard E.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1994/4
Y1 - 1994/4
N2 - Purpose: This study was undertaken to evaluate the feasibility and therapeutic effect of high-dose chemoradiotherapy with autologous or allogeneic bone marrow transplantation (BMT) in patients with advanced chronic lymphocytic leukemia (CLL) who relapse after fludarabine treatment. Patients and Methods: Twenty-two patients with advanced CLL received high- dose cyclophosphamide, total-body irradiation, and BMT. Eleven patients with relapsed CLL received autologous BMT with marrow collected during a prior fludarabine-induced remission; leukemia cells were depleted from the autologous marrow in seven patients using an anti-CD19 monoclonal antibody and immunomagnetic separation. Eleven patients received allogeneic or syngeneic BMT, seven of whom had refractory Rai stage III or IV disease. Results: Six autologous transplant recipients achieved a complete remission (CR), four a nodular CR (nCR), and one a partial remission (PR). Two recurred with CLL, and three developed Richter's transformation. Two patients had recurrence of immune cytopenias while in morphologic remission; one of these patients died of cytomegalovirus pneumonia. Six of 11 patients survive in remission 2 to 29 months following BMT. Of the 11 patients who received allogeneic or syngeneic BMT, seven achieved a CR, two a nCR, and one a PR; 10 survive 2 to 36 months following BMT. Conclusion: These data indicate that high-dose chemotherapy with allogeneic BMT is effective at producing CRs in patients with CLL. Autologous transplantation in CLL is feasible and is capable of producing remissions in patients with advanced CLL. Further studies are warranted to assess the role of BMT in the treatment of CLL.
AB - Purpose: This study was undertaken to evaluate the feasibility and therapeutic effect of high-dose chemoradiotherapy with autologous or allogeneic bone marrow transplantation (BMT) in patients with advanced chronic lymphocytic leukemia (CLL) who relapse after fludarabine treatment. Patients and Methods: Twenty-two patients with advanced CLL received high- dose cyclophosphamide, total-body irradiation, and BMT. Eleven patients with relapsed CLL received autologous BMT with marrow collected during a prior fludarabine-induced remission; leukemia cells were depleted from the autologous marrow in seven patients using an anti-CD19 monoclonal antibody and immunomagnetic separation. Eleven patients received allogeneic or syngeneic BMT, seven of whom had refractory Rai stage III or IV disease. Results: Six autologous transplant recipients achieved a complete remission (CR), four a nodular CR (nCR), and one a partial remission (PR). Two recurred with CLL, and three developed Richter's transformation. Two patients had recurrence of immune cytopenias while in morphologic remission; one of these patients died of cytomegalovirus pneumonia. Six of 11 patients survive in remission 2 to 29 months following BMT. Of the 11 patients who received allogeneic or syngeneic BMT, seven achieved a CR, two a nCR, and one a PR; 10 survive 2 to 36 months following BMT. Conclusion: These data indicate that high-dose chemotherapy with allogeneic BMT is effective at producing CRs in patients with CLL. Autologous transplantation in CLL is feasible and is capable of producing remissions in patients with advanced CLL. Further studies are warranted to assess the role of BMT in the treatment of CLL.
UR - http://www.scopus.com/inward/record.url?scp=0028289052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028289052&partnerID=8YFLogxK
U2 - 10.1200/JCO.1994.12.4.748
DO - 10.1200/JCO.1994.12.4.748
M3 - Article
C2 - 8151318
AN - SCOPUS:0028289052
SN - 0732-183X
VL - 12
SP - 748
EP - 758
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 4
ER -